Recombinant Human TICAM2

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Documents del producto
Product specifications
Category | Proteins and Peptides |
Immunogen Target | 1-235 |
Host | E.Coli |
Origin | Human |
Observed MW | 25.7 kDa |
Expression | Recombinant |
Purity | Greater than 95% by SDS-PAGE gel analyses |
Purification | His tag |
Size 1 | 50μg |
Size 2 | 200μg |
Size 3 | 1mg |
Form | Lyophilized from a 0.2um filtered solution in PBS with 5% trehalose, pH7.4 |
Tested Applications | Western Blot,ELISA |
Buffer | Reconstitute with Sterile distilled water |
Availability | 3-4 weeks |
Storage | -20°C for 12 months as lyophilized;2-8°C for 1 month under sterile conditions after reconstitution |
UniProt ID | Q86XR7 |
Alias | MyD88-4, TICAM-2, TIRAP3, TIRP, TRAM, toll like receptor adaptor molecule 2 |
Background | Proteins TICAM2 |
Status | RUO |
Note | This product is for research use only. |
TICAM2, also known as TRAM (TRIF-related adaptor molecule), is an adaptor protein that functions specifically in Toll-like receptor 4 (TLR4) signaling. It facilitates MyD88-independent pathways, mediating the activation of IRF3 and NF-κB to induce type I interferon and pro-inflammatory cytokine production. TICAM2 acts as a bridge between TLR4 and TICAM1, enabling signaling responses to lipopolysaccharides (LPS) and other pathogen-associated molecular patterns (PAMPs) in Gram-negative bacterial infections. TICAM2 is expressed primarily in immune and epithelial cells, where it contributes to early innate immune responses. Dysregulation of TICAM2 impairs TLR4-mediated IFN-β production and inflammatory signaling, leading to defective immune responses to bacterial infections or chronic inflammation in certain conditions. Knockout studies reveal a loss of MyD88-independent signaling, reduced IRF3 activation, and increased susceptibility to bacterial infections, underscoring its specific and essential role in TLR4 signaling pathways.
Related Products

anti- TICAM2 antibody
Functions as sorting adapter in LPS-TLR4 signaling to regulate the MYD88-independent pathway during the innate immune response to LPS. Physically bridges TLR4 and TICAM1 and functionally transmits LPS-TRL4 signal to TICAM1; signaling is proposed to occur in early endosomes after endocytosis of TLR4. May also be involved in IL1-triggered NF-kappa-B activation, functioning upstream of IRAK1, IRAK2, TRAF6, and IKBKB; however, reports are controversial. Involved in IL-18 signaling and is proposed to function as a sorting adaptor for MYD88 in IL-18 signaling during adaptive immune response. Isoform 2: Proposed to inhibit LPS-TLR4 signaling at the late endosome by interaction with isoform 1 thereby disrupting the association of isoform 1 with TICAM1. May be involved in TLR4 degradation in late endosomes.
Ver Producto
Recombinant Human TICAM2
Ver Producto
TIR Domain-Containing Adapter Molecule 2 (TICAM2) Antibody
TICAM2 Antibody is a Rabbit Polyclonal Antibody against TICAM2.
Ver Producto